LANCET ONCOL: Selumetinib with docetaxel combination therapy of advanced NSCLC KRAS mutations good effect
Multinational joint research shows that for previous KRAS mutations treated advanced non small cell lung cancer (NSCLC) in patients with a single treatment with docetaxel compared to treatment combined with MEK inhibitor Selumetinib better. November 28th online paper published in "Lancet Oncology" (Lancet Oncol).
The study revealed that, Selumetinib group and the placebo group, the median overall survival (OS) of 9.4 months, respectively, and 5.2 months, median progression-free survival (PFS) of 5.3 months, respectively, and 2.1 months, objective response rate of 37% and 0; groups 3 and above, the incidence of adverse reactions were 82% and 67%.
LANCET ONCOL: Selumetinib with docetaxel combination therapy of advanced NSCLC KRAS mutations good effect
ReplyDeleteMultinational joint research shows that for previous KRAS mutations treated advanced non small cell lung cancer (NSCLC) in patients with a single treatment with docetaxel compared to treatment combined with MEK inhibitor Selumetinib better. November 28th online paper published in "Lancet Oncology" (Lancet Oncol).
The study revealed that, Selumetinib group and the placebo group, the median overall survival (OS) of 9.4 months, respectively, and 5.2 months, median progression-free survival (PFS) of 5.3 months, respectively, and 2.1 months, objective response rate of 37% and 0; groups 3 and above, the incidence of adverse reactions were 82% and 67%.
Medchemexpress Can provide the above product,its website:www.medchemexpress.com
Sumanirole maleate
Quetiapine fumarate
SB-277011
Pramipexole dihydrochloride
Org 27569
LY341495
Dapagliflozin
Naltrexone
Tapentadol hydrochloride
Vorinostat